The most common ICBs refer to blocking immune inhibitory receptors CTLA4 and PD‐1 on T cells, or PD‐L1 on tumor cells and tumor‐infiltrating immune cells using antagonistic antibodies. The gene discussed is CD274; the disease is neoplasm.